Muhamed Baljevic is an Oncology physician. OpenAlex indexes 151 publications with 3,216 citations (h-index 20); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 372320001
Telephone
615-322-3000Provider last certified this registry record 22 Mar 2022.
Clinical trials
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Sponsor: National Cancer Institute (NCI)
- Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
Sponsor: University of Nebraska
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20254 payments$74,900openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202524 payments$14,848openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.1%Thalidomide Analog34.6%Revlimid63%Lenalidomide21%Pomalyst16%Part D<11 patientsKinase inhibitor2.3%Brukinsa100%Part D<11 patients+ 1 more class in this area
Anti-infectives
38.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor31.9%Valacyclovir100%Part D≥48 patientsShort-acting sulfonamides6.2%Sulfamethoxazole-Trimethoprim100%Part D≥12 patientsNervous system
11%Gabapentinoids7.7%Gabapentin100%Part D≥11 patientsSNRI3.3%Duloxetine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2025 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2026 - NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Journal of the National Comprehensive Cancer Network
2025 - Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial
Bone Marrow Transplantation
2025 - Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”